Latest news with #ADMA
Yahoo
07-05-2025
- Business
- Yahoo
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings?
ADMA Biologics ADMA is scheduled to report first-quarter 2025 results on May 7, after market close. The Zacks Consensus Estimate for sales and earnings is pegged at $119.1 million and 16 cents per share, respectively. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Earnings estimate for 2025 has increased to 71 cents from 69 cents per share over the past 60 days, and the same for 2026 has improved to 93 cents from 87 cents. Zacks Investment Research Image Source: Zacks Investment Research ADMA's Earnings Surprise History ADMA has a mixed track record. Its earnings beat estimates in three of the trailing four quarters and missed in the remaining one, delivering an average surprise of 32.8%. However, in the previously reported quarter, the company's earnings missed estimates by 6.67%. Zacks Investment Research Image Source: Zacks Investment Research What Our Model Predicts for ADMA Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Earnings ESP for ADMA is 0.00%. The company currently carries a Zacks Rank #2. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Factors Influencing ADMA's Q1 Results ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases. The company's top line currently comprises sales of three FDA-approved products, which are Bivigam (an Intravenous Immune Globulin [IVIG] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus). Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. These antibodies are proteins used by the body's immune system to neutralize microbes, such as bacteria and viruses, and prevent infection and disease. Asceniv is indicated for the treatment of PIDD or inborn errors of immunity in adults and adolescents. It is manufactured using ADMA's unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma with respiratory syncytial virus plasma obtained from donors tested using the company's proprietary microneutralization assay. Increased sales of Asceniv have likely fueled the top line in the first quarter. Gross margin has also likely improved due to a significantly more favorable mix of high margin immunoglobulin (IG) sales.
Yahoo
29-04-2025
- Business
- Yahoo
Why ADMA Biologics, Inc. (ADMA) Surged on Monday
We recently published an article titled . In this article, we are going to take a look at where ADMA Biologics, Inc. (NASDAQ:ADMA) stands against the other stocks. The stock market kicked off the trading week on a mixed note, with two major indices ending in the green, as investors continued to digest more corporate earnings results. Among the bellwether indices, only the Nasdaq ended in the red, dropping 0.10 percent. In contrast, the Dow Jones grew by 0.28 percent and the S&P 500 inched up by 0.06 percent. Meanwhile, 10 companies mirrored a broader market optimism, as investors snapped up shares ahead of their first-quarter earnings performance in the next few days. To come up with the list, we considered only the companies with a $2-billion market capitalization and $5-million trading volume. An independent distributor in their pharmacy with a range of biopharmaceutical products on display. ADMA Biologics, Inc. (NASDAQ:ADMA) soared to a new all-time high on Monday after securing the approval of the Food and Drug Administration (FDA) for its innovative yield enhancement production process. According to the company, the innovative process has demonstrated an ability to increase production yields by approximately 20 percent from the same starting plasma volume. Following the announcement, ADMA Biologics, Inc. (NASDAQ:ADMA) touched a new record high of $25.67 at intraday trading before early profit-taking pulled its price slightly lower to end the day just up by 12.12 percent at $24.51 apiece. 'This approval represents a pivotal milestone for ADMA, unlocking the opportunity for meaningful acceleration in our revenue and earnings trajectory beginning in late 2025 and accelerating further into 2026 and beyond,' said Adam Grossman, president and CEO of ADMA Biologics, Inc. (NASDAQ:ADMA). 'Looking ahead, we are excited to continue to advance our internal R&D platform—further optimizing production capabilities and progressing novel pipeline programs, most notably SG-001, our pre-clinical, investigative hyperimmune globulin targeting S. pneumonia, which exemplifies our commitment to product and process innovation,' he added. Overall ADMA ranks 3rd on our list of the best performing stocks on Monday. While we acknowledge the potential of ADMA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ADMA but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
23-04-2025
- Business
- Yahoo
Why ADMA Biologics Inc. (ADMA) Performed Worst On Monday?
We recently published a list of . In this article, we are going to take a look at where ADMA Biologics Inc. (NASDAQ:ADMA) stands against other best worst-performing companies on Monday Wall Street kicked off the trading week on a sour note anew as investors continued to digest the impact of President Donald Trump's tariff policies and his criticism of the Federal Reserve. The tech-heavy Nasdaq fell the most among the major indices, down 2.55 percent, followed by the Dow Jones at 2.48 percent, and the S&P 500 at 2.36 percent. Ten companies mirrored the market bloodbath, booking significant losses during the day. In this article, we have listed the 10 worst-performing companies on Monday and detailed the reasons behind their declines. To come up with the list, we considered only the stocks with a $2 billion market capitalization and $5 million in trading volume. An independent distributor in their pharmacy with a range of biopharmaceutical products on display. ADMA Biologics saw its share price decrease by 7.84 percent on Monday to close at $19.64 apiece as investors sold off amid an overall market pessimism and the lack of fresh catalysts to boost investing appetite. Last week, ADMA saw a rally in its shares following announcements that it sees minimal to no impact from the ongoing trade tensions globally. In a news release, ADMA President and CEO Adam Grossman underscored the company being a fully US-based firm, with manufacturing operations, market sales, and customer engagements conducted exclusively within the US. 'The tariffs that have been implemented on foreign goods, services, and manufacturing should have no impact on ADMA and its supply chain or production operations,' he said. 'Our strategic infrastructure not only ensures enhanced supply chain robustness, resilience, and regulatory compliance but also aligns with increasing federal and private sector preferences for US-made products and services,' he added. ADMA is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics for treating immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Overall, ADMA ranks 7th on our list of worst-performing companies on Monday. While we acknowledge the potential of ADMA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ADMA but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
16-04-2025
- Business
- Yahoo
Why ADMA Biologics, Inc. (ADMA) Skyrocketed On Tuesday?
We recently published a list of . In this article, we are going to take a look at where ADMA Biologics, Inc. (NASDAQ:ADMA) stands against other firms that end stronger on Tuesday. A muted trading persisted on the stock market on Tuesday, with major indices ending in the red, recording minimal losses while digesting President Donald Trump's tariff policies. The Dow Jones declined by 0.38 percent, the S&P 500 dipped by 0.17 percent, while the tech-heavy Nasdaq dipped by 0.05 percent. Ten companies bucked a broader market pessimism, booking modest gains during the session. In this article, we have identified the reasons behind their gains. To come up with the list, we only considered the stocks with $2 billion market capitalization and $5 million trading volume. An independent distributor in their pharmacy with a range of biopharmaceutical products on display. ADMA Biologics rallied for a third straight day on Tuesday, adding 5.93 percent to end at $22.15 as investor sentiment was buoyed by its business optimism, saying it sees only minimal to no impact from the ongoing trade tensions globally. In a statement earlier this week, ADMA President and CEO Adam Grossman underscored the company being a fully US-based firm, with manufacturing operations, market sales, and customer engagements conducted exclusively within the US. 'The tariffs that have been implemented on foreign goods, services, and manufacturing should have no impact on ADMA and its supply chain or production operations,' he said. 'Our strategic infrastructure not only ensures enhanced supply chain robustness, resilience, and regulatory compliance but also aligns with increasing federal and private sector preferences for US-made products and services,' he added. ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics for treating immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Overall, ADMA ranks 4th on our list of firms that end stronger on Tuesday. While we acknowledge the potential of ADMA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ADMA but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
25-02-2025
- Business
- Yahoo
ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Conference Call Scheduled for March 3, 2025, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ('ADMA' or the 'Company'), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report fourth quarter and full year 2024 financial results on March 3, 2025, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call, please dial (888) 596-4144 and refer to conference ID 5201334. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available located under 'Events & Webcasts' in the investor section of the Company's website at About ADMA Biologics, Inc. (ADMA) ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products. ADMA's mission is to manufacture, market and develop specialty biologics and human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit INVESTOR RELATIONS CONTACT:Argot Partners | 212-600-1902 | ADMA@
